Drug Trial Radar · NCT06497504
Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
153
Actual
Start
Sep 17, 2024
Primary completion
Apr 22, 2027
Study completion Apr 22, 2027
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Jul 11, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy and safety of bepirovirsen compared to placebo in participants with human immunodeficiency virus (HIV)/hepatitis B virus (HBV) co-infection.
Conditions
- Hepatitis B
Interventions
BepirovirsenDrug
Bepirovirsen will be administered.
PlaceboDrug
Placebo will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants achieving hepatitis B virus (HBV) virologic response at 36 weeks after scheduled end of study treatment in absence of rescue medicationTime frame: At study week 60
Locations
51 sites in 10 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Bakersfield, California
GSK Investigational Site
San Francisco, California
GSK Investigational Site
Orlando, Florida
GSK Investigational Site
West Palm Beach, Florida
GSK Investigational Site
Baltimore, Maryland
GSK Investigational Site
Minneapolis, Minnesota
GSK Investigational Site
Hillsborough, New Jersey
GSK Investigational Site
Almagro, Argentina
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
La Plata, Argentina
GSK Investigational Site
Rosario, Argentina
GSK Investigational Site
Aracaju, Brazil
GSK Investigational Site
Campinas, Brazil
GSK Investigational Site
Curitiba, Brazil
GSK Investigational Site
Manaus, Brazil
GSK Investigational Site
Salvador, Brazil
GSK Investigational Site
São Paulo, Brazil
GSK Investigational Site
Ottawa, Ontario, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Montreal, Quebec, Canada
GSK Investigational Site
Montreal, Quebec, Canada
GSK Investigational Site
Québec, Quebec, Canada
GSK Investigational Site
Marseille, France
GSK Investigational Site
Melun, France
GSK Investigational Site
Montpellier, France
GSK Investigational Site
Nantes, France
GSK Investigational Site
Paris, France
GSK Investigational Site
Paris, France
GSK Investigational Site
Genova, Italy
GSK Investigational Site
Milan, Italy
GSK Investigational Site
Milan, Italy
GSK Investigational Site
Naples, Italy
GSK Investigational Site
Roma, Italy
GSK Investigational Site
Sassari, Italy
GSK Investigational Site
Ekurhuleni, South Africa
GSK Investigational Site
Johannesburg, South Africa
GSK Investigational Site
Durban, KwaZulu-Natal, South Africa
GSK Investigational Site
Barcelona, Spain
Showing 40 of 51 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.